Organogenesis Holdings (ORGO) Cash from Investing Activities (2018 - 2026)

Organogenesis Holdings' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 13.24% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$13.7 million (down 19.54% YoY), while the FY2025 annual figure was -$14.2 million, down 41.06% from the prior year.
• Cash from Investing Activities was -$3.1 million for Q1 2026 at Organogenesis Holdings, up from -$4.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$1.9 million in Q2 2024 to a low of -$10.7 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged -$5.0 million across 5 years, with a median of -$3.6 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities sank 103.86% in 2022, then soared 74.93% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$10.7 million in 2022, then surged by 68.81% to -$3.3 million in 2023, then dropped by 1.11% to -$3.4 million in 2024, then slumped by 38.41% to -$4.7 million in 2025, then surged by 32.37% to -$3.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$3.1 million (Q1 2026), -$4.7 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.